Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

Choroideremia Clinical Trial

Official title:

A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02341807
• Other study ID #: AAV2-hCHM-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 15, 2015
• Est. completion date: October 12, 2022

Study information

• Verified date: January 2024
• Source: Spark Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.

Description:

The primary objective is to evaluate the safety and tolerability of subretinal administration of AAV2-hCHM, in an inter-subject group dose escalation in individuals with choroideremia, based on a comprehensive clinical monitoring plan. The secondary objectives are to define the dose of AAV2-hCHM required to achieve stable, or improved, visual function/functional vision and to assess development of immune responses to adeno-associated virus vector, serotype 2 (AAV2) and Rab escort protein 1 (REP-1).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 12, 2022
• Est. primary completion date: October 12, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male at least 18 years of age diagnosed with CHM gene mutation
• Central visual field (VF) <30° in any of the 24 meridians (using Goldmann perimetry III4e isopter) in the eye to be injected
• Any evidence of functioning outer retinal cells within the central 10°

Exclusion Criteria:

• Previous history of ocular inflammatory disease (uveitis)
• Prior intraocular surgery within six months
• Participation in a previous gene therapy research trial within one year of enrollment or participation in any other ocular gene therapy trial
• Participation in a clinical study with an investigational drug in the past six months
• Grossly asymmetrical disease, or other eye morbidity, which may render the contralateral eye ineffective as a control
• Visual acuity <20/200 on standard Early Treatment of Diabetic Retinopathy Study (ETDRS) testing in the eye to be injected
• Presence of disease which may preclude the participant from participation in this trial
• Use of medications known to be neuroprotective or retino-toxic that could potentially interfere with the disease process and/or cause ocular adverse events; individuals who discontinue use of these compounds for 6 months may become eligible
• Identification by the investigator as being unable or unwilling to perform/be compliant with study procedures.

Related Conditions & MeSH terms

• CHM (Choroideremia) Gene Mutations
• Choroideremia

Intervention

Biological:
• AAV2-hCHM
Comparison of different dosages of AAV2-hCHM

Locations

Country	Name	City	State
United States	Massachusetts Eye and Ear Infirmary	Boston	Massachusetts
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Spark Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were AEs that occurred on or after the day of study drug administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.	Up to 5 years
Secondary	Number of Participants With Anti-AAV2 Viral Capsid Antibody Titers That Rose Above Baseline At Least Once After Dosing	Number of participants who were found to have quantifiable levels (above 1.55 micrograms [µg]/milliliter [mL]) of Anti-AAV2 viral capsid antibodies titer in the blood at least 1 study visit up to 2 years were reported.	Up to 2 years
Secondary	Number of Participants With Cellular Immune Response to AAV2 Through Interferon Gamma Enzyme-linked Immunosorbent Spot (ELISpot) Assay	Interferon gamma ELISpot assays were used to evaluate the cellular immune response to AAV2 antigen in collected peripheral blood mononuclear cell (PBMC) samples. Number of participants who demonstrated immune response to the AAV2 antigen were reported.	Up to 2 years
Secondary	Number of Participants With Cellular Immune Response to Rab Escore Protein-1 (REP-1) Through Interferon Gamma ELISPOT Assay	Interferon gamma ELISpot assays were used to evaluate the cellular immune response to REP-1 antigen in collected PBMC samples. Number of participants who demonstrated immune response to the REP-1 antigen were reported.	Up to 2 years